Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company is headquartered in Toronto, Canada.
Vaxil Bio (CVE: VXL) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.1150 CAD on 19 November 2026, down 37.8% over 52 weeks. Its 52-week range is 0.1000 CAD to 0.2900 CAD: the price is 60.3% below the high and 15.0% above the low.
Its market capitalisation is 458.16K CAD.
Vaxil Bio reports return on equity of 38.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 464.00K CAD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 26 November 2026.